NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27 August 2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended Tecfidera (dimethyl fumarate) in the treatment of multiple sclerosis, developed by US biotech firm Biogen Idec (Nasdaq: BIIB) following a final appraisal determination last month. This means the UK’s national health service now has an obligation to begin funding the drug for eligible patients within the next three months.

The NICE has approved Tecfidera as treatment for adults with relapsing-remitting multiple sclerosis if they do not have highly active or rapidly-evolving severe relapsing-remitting MS and the manufacturer provides it with the discount agreed in the patient access scheme.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK